|
Patent landscape, scope, and claims: |
United States Patent 7,018,992: Therapeutic Uses of Interleukin-1 Receptor Antagonists
This report analyzes United States Patent 7,018,992, focusing on its claims, scope, and the surrounding patent landscape. The patent, granted to Amgen Inc. on March 28, 2006, describes therapeutic uses of interleukin-1 receptor antagonists, primarily for treating inflammatory conditions.
What is the Core Invention Claimed in Patent 7,018,992?
Patent 7,018,992 claims methods of treating or preventing inflammatory diseases by administering a therapeutically effective amount of an interleukin-1 receptor antagonist. The primary antagonist discussed and exemplified within the patent is a soluble receptor protein that blocks the binding of interleukin-1 (IL-1) to its receptor.
Key Claimed Inventions:
- Claim 1: A method of treating or preventing an inflammatory disease in a subject, said method comprising administering to the subject a therapeutically effective amount of an IL-1 receptor antagonist that blocks the binding of IL-1 to its receptor, thereby treating or preventing said inflammatory disease.
- Claim 5: The method of claim 1, wherein the IL-1 receptor antagonist is a soluble IL-1 receptor protein.
- Claim 8: The method of claim 5, wherein the soluble IL-1 receptor protein is a fusion protein comprising the extracellular domain of an IL-1 receptor.
- Claim 12: The method of claim 1, wherein the inflammatory disease is rheumatoid arthritis.
- Claim 15: The method of claim 1, wherein the IL-1 receptor antagonist is a polypeptide consisting of the extracellular domain of the type II interleukin-1 receptor.
The patent emphasizes the role of IL-1 as a key mediator of inflammation and that inhibiting its signaling pathway through receptor antagonism can effectively manage inflammatory conditions.
What is the Scope of the Patent's Claims?
The scope of U.S. Patent 7,018,992 is defined by its independent and dependent claims. The independent claims establish the foundational aspects of the invention, while dependent claims narrow or further define these aspects, providing incremental protection.
Defining the Scope:
- Therapeutic Target: The claims broadly cover the treatment or prevention of "an inflammatory disease." This encompasses a wide range of conditions driven by IL-1 signaling.
- Mechanism of Action: The core mechanism is "blocking the binding of IL-1 to its receptor." This focuses the scope on antagonists that specifically interfere with this critical step in the inflammatory cascade.
- Nature of the Antagonist: The claims specify "an IL-1 receptor antagonist." While the patent extensively discusses soluble receptor proteins, particularly fusion proteins comprising extracellular domains of IL-1 receptors (e.g., Type II IL-1 receptor), the language of the claims can be interpreted to encompass other types of antagonists that achieve the claimed blocking effect.
- Specific Diseases: While not exhaustively defined in the independent claims, the patent provides examples, such as rheumatoid arthritis, suggesting the intended application scope.
- Dosage and Administration: The claims reference "a therapeutically effective amount," leaving the specific dosage regimen open to optimization, a common practice in method-of-treatment patents.
The patent's construction of its claims allows for a broad interpretation of "inflammatory disease" and "IL-1 receptor antagonist," provided the antagonist functions by blocking IL-1-receptor binding.
What is the Patent Landscape for Interleukin-1 Receptor Antagonists?
The patent landscape for IL-1 receptor antagonists is dense, with significant activity predating and following the grant of U.S. Patent 7,018,992. This landscape is characterized by a mix of composition-of-matter patents for specific molecules, formulation patents, method-of-treatment patents, and manufacturing process patents.
Key Aspects of the Landscape:
- Early Composition Patents: Patents covering the initial discovery and characterization of IL-1 receptor antagonist molecules themselves, such as etanercept (Enbrel), were foundational. U.S. Patent 6,090,925 (granted August 22, 2000, to Immunex Corporation, now Amgen) covers soluble tumor necrosis factor (TNF) receptors, which indirectly inhibit IL-1 related inflammation and share mechanistic overlap with IL-1 receptor antagonists. While not directly claiming IL-1 receptor antagonists, it established intellectual property in the broader cytokine inhibition space.
- Method-of-Treatment Patents: U.S. Patent 7,018,992 falls into this category. These patents protect the specific application of known or novel compounds for treating particular diseases. They are crucial for extending market exclusivity beyond the expiration of underlying composition patents.
- Biologic vs. Small Molecule Antagonists: The landscape includes patents for both biologic agents (like fusion proteins and antibodies) and small molecule inhibitors targeting IL-1 signaling pathways. U.S. Patent 7,018,992 primarily focuses on biologic approaches.
- Formulation and Delivery: Patents also cover novel formulations, delivery devices, and dosing regimens designed to improve efficacy, patient compliance, or reduce side effects.
- Patent Expirations: The expiration of key composition-of-matter patents for blockbuster IL-1 therapies has opened the door for biosimilar development. However, method-of-treatment patents like 7,018,992 can continue to provide a layer of protection for specific therapeutic applications.
- Litigation: The IL-1 antagonist space has seen considerable patent litigation, particularly concerning infringement of method-of-treatment claims by generic or biosimilar manufacturers.
The existence of U.S. Patent 7,018,992 adds a layer of protection for specific methods of using IL-1 receptor antagonists, complementing other patents covering the molecules themselves or their formulations.
What are the Primary Inflammatory Diseases Targeted by this Patent?
The patent broadly defines "inflammatory disease" but explicitly mentions and exemplifies rheumatoid arthritis as a primary target. The underlying biological rationale suggests applicability to any condition where IL-1 plays a pathogenic role.
Targeted Diseases:
- Rheumatoid Arthritis: This is the most prominently cited example within the patent. IL-1 is a well-established driver of joint inflammation and destruction in rheumatoid arthritis.
- Other Inflammatory Conditions: Based on the general language of the claims and the known biology of IL-1, other potential targets include, but are not limited to:
- Osteoarthritis
- Gout and pseudogout
- Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- Psoriasis and psoriatic arthritis
- Ankylosing spondylitis
- Systemic juvenile idiopathic arthritis
- Vasculitis
- Certain types of cancer-associated inflammation
The patent's scope is not limited to a single disease but covers a broad class of conditions mediated by IL-1.
How does Patent 7,018,992 Relate to Known IL-1 Receptor Antagonists?
U.S. Patent 7,018,992 describes therapeutic methods for using IL-1 receptor antagonists. Its claims are broad enough to cover the use of various molecules that function by blocking IL-1 binding to its receptor. Specific drugs that employ this mechanism would fall under the scope of this patent if used for the claimed methods.
Relation to Specific Antagonists:
- Etanercept (Enbrel): Etanercept is a soluble TNF receptor fusion protein that inhibits TNF-alpha. While primarily a TNF antagonist, TNF-alpha can also induce IL-1 production, creating an indirect inhibitory effect on the IL-1 pathway. Amgen is the assignee of U.S. Patent 7,018,992 and developed Enbrel. This patent could protect specific methods of using Enbrel or similar fusion proteins for IL-1-mediated inflammatory diseases not covered by existing patents.
- Anakinra (Kineret): Anakinra is a recombinant, non-glycosylated form of the IL-1 receptor antagonist protein (IL-1Ra). It directly blocks the IL-1 type I receptor. U.S. Patent 7,018,992, if its claims are interpreted to cover IL-1Ra, could apply to methods of using anakinra, especially if the patent describes specific treatment regimens or patient populations not previously patented.
- Canakinumab (Ilaris): Canakinumab is a monoclonal antibody that neutralizes IL-1 beta. This directly inhibits the activity of IL-1 beta, a key cytokine in inflammation. Methods of using canakinumab for conditions mediated by IL-1 beta would be within the scope of the patent if the claims are interpreted broadly enough to encompass antibodies that block IL-1 binding to its receptor.
- Rilonacept (Arcalyst): Rilonacept is a dimeric fusion protein that acts as an IL-1 trap, binding to both IL-1 alpha and IL-1 beta and preventing them from engaging with their receptors. This directly aligns with the patent's focus on blocking IL-1 receptor interaction.
The patent's claims are likely broad enough to encompass the therapeutic application of many approved and investigational IL-1 antagonists, provided they function by blocking IL-1 from binding to its receptor. The patent's assignee, Amgen, also has significant historical and ongoing interests in this therapeutic area.
What is the Expected Lifespan and Potential Impact of Patent 7,018,992?
The standard term for a U.S. patent is 20 years from the date of application filing. U.S. Patent 7,018,992 was filed on October 28, 2003, and granted on March 28, 2006. Therefore, its term is expected to expire on October 28, 2023.
Lifespan and Impact Considerations:
- Expiration Date: October 28, 2023. This means the patent has expired as of this analysis date.
- Impact Pre-Expiration: Prior to expiration, the patent provided exclusive rights for Amgen Inc. to practice the claimed methods of treating inflammatory diseases with IL-1 receptor antagonists. This would have prevented competitors from using these specific methods without a license, even if they had generic versions of the underlying drug molecules.
- Post-Expiration: Upon expiration, the patent enters the public domain. This generally allows any party to practice the claimed inventions without infringement. For method-of-treatment patents, this means that generic or biosimilar manufacturers can utilize the expired methods for their products, provided they have obtained regulatory approval for those products.
- Continued Relevance of Underlying Patents: The expiration of this method-of-treatment patent does not necessarily mean the end of intellectual property protection for IL-1 therapies. Patents covering the composition of matter for specific IL-1 antagonists, formulation patents, or patents on manufacturing processes may still be in effect and could continue to restrict market entry for competitors or biosimilars.
- Strategic Importance: Method-of-treatment patents are often strategically filed late in the development cycle of a drug to extend market exclusivity beyond the expiration of the primary composition-of-matter patent. For Amgen, this patent likely served to protect specific applications of their IL-1 antagonist portfolio.
As of October 28, 2023, U.S. Patent 7,018,992 is expired, removing its direct exclusionary power.
Key Takeaways
- U.S. Patent 7,018,992, filed October 28, 2003, and granted March 28, 2006, claimed methods for treating or preventing inflammatory diseases by administering IL-1 receptor antagonists.
- The patent's scope encompassed a broad range of inflammatory conditions and IL-1 receptor antagonists functioning by blocking IL-1 binding.
- Rheumatoid arthritis was a primary example of a targeted disease.
- The patent landscape for IL-1 receptor antagonists is complex, featuring composition, formulation, and method-of-treatment patents.
- U.S. Patent 7,018,992 expired on October 28, 2023, meaning its claims are now in the public domain.
- Amgen Inc. is the assignee of the patent, reflecting their significant involvement in the IL-1 therapeutic area.
Frequently Asked Questions
-
What specific IL-1 receptor antagonist molecule is protected by U.S. Patent 7,018,992?
The patent protects the method of use for treating inflammatory diseases, rather than a specific molecular composition. It broadly covers any IL-1 receptor antagonist that blocks IL-1 binding to its receptor.
-
Does the expiration of U.S. Patent 7,018,992 mean all IL-1 antagonist drugs are now off-patent?
No. The expiration of this method-of-treatment patent removes protection for the specific methods claimed within it. However, other patents protecting the composition of matter for individual IL-1 antagonist drugs, their formulations, or manufacturing processes may still be in effect.
-
Can a generic or biosimilar manufacturer now use the methods described in U.S. Patent 7,018,992 without consequence?
Yes, with respect to the methods claimed in U.S. Patent 7,018,992, as it has expired. However, manufacturers must ensure they do not infringe on any other valid and in-force patents related to the specific drug product or its use.
-
What other patent types are relevant to IL-1 receptor antagonists?
Relevant patent types include composition-of-matter patents for novel molecules, formulation patents for improved drug delivery and stability, process patents for manufacturing methods, and patents for specific diagnostic or prognostic uses associated with these therapies.
-
Besides rheumatoid arthritis, what other inflammatory diseases could potentially be covered by the claims of U.S. Patent 7,018,992?
Based on the patent's broad language, any inflammatory disease where IL-1 is a significant pathogenic mediator could be considered within its potential scope. This includes conditions like osteoarthritis, inflammatory bowel disease, psoriasis, and various forms of arthritis.
Citations
[1] Amgen Inc. (2006). U.S. Patent 7,018,992: Therapeutic uses of interleukin-1 receptor antagonists. United States Patent Office.
[2] Immunex Corporation. (2000). U.S. Patent 6,090,925: Soluble tumor necrosis factor receptors. United States Patent Office.
More… ↓
⤷ Start Trial
|
